Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 11/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8508730 | 0.84 | EPHX1 (0.59) | EPHX1TSHRSLC6A2ADRA1AHTR2B | |
| SCHEMBL28357174 | 0.82 | EPHX1 (0.68) | EPHX1TSHR | |
| SCHEMBL28353670 | 0.82 | EPHX1 (0.68) | EPHX1TSHR | |
| SCHEMBL28353669 | 0.82 | EPHX1 (0.68) | EPHX1TSHR | |
| SCHEMBL4113792 | 0.82 | EPHX1 (0.68) | EPHX1TSHR | |
| SCHEMBL28353827 | 0.82 | EPHX1 (0.68) | EPHX1TSHR | |
| SCHEMBL28357172 | 0.82 | EPHX1 (0.68) | EPHX1TSHR | |
| SCHEMBL13773134 | 0.79 | EPHX1 (0.44) | EPHX1TSHR | |
| SCHEMBL20634564 | 0.79 | EPHX1 (0.44) | EPHX1TSHR | |
| SCHEMBL13773136 | 0.79 | EPHX1 (0.44) | EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| EP-1317460-A4 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | UNIV COLORADO STATE RES FOUND (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1317460-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-0724569-B1 | PROCESS FOR THE PREPARATION OF AN OXIRANE, AZIRIDINE OR CYCLOPROPANE | AVECIA LTD (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002018391-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-03-07 | — | — | WO | disclosed |
| US-5703246-A | REACTING AN ORGANOMETALLIC COMPOUND WITH ORGANOSULFUR COMPOUND | ZENECA LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| EP-0724569-A1 | PROCESS FOR THE PREPARATION OF AN OXIRANE, AZIRIDINE OR CYCLOPROPANE | ZENECA LIMITED (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011230-A1 | PROCESS FOR THE PREPARATION OF AN OXIRANE, AZIRIDINE OR CYCLOPROPANE | ZENECA LIMITED (GB) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | EPHX1 2296/4885TSHR 3396/4885SLC6A2 4824/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | EPHX1 2887/4885TSHR 3332/4885SLC6A2 4833/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | EPHX1 3640/4885TSHR 4120/4885SLC6A2 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.